Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma
EU Approval Granted For AstraZeneca's Amgen-Partnered Therapy
Executive Summary
With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.
You may also be interested in...
Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes
The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.
AstraZeneca’s Fasenra Future Weakened By Pivotal Eosinophilic Esophagitis Trial Flop
The major’s monoclonal antibody drug missed one of two primary endpoints in a late-stage eosinophilic esophagitis trial in the second setback this year to plans for label expansion beyond the asthma maintenance setting.
AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.